KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Operating Expenses (2018 - 2025)

Adaptive Biotechnologies' Other Operating Expenses history spans 8 years, with the latest figure at $43.1 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses rose 7.94% year-over-year to $43.1 million; the TTM value through Dec 2025 reached $167.6 million, up 2.37%, while the annual FY2025 figure was $167.6 million, 2.37% up from the prior year.
  • Other Operating Expenses for Q4 2025 was $43.1 million at Adaptive Biotechnologies, up from $42.1 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $67.4 million in Q4 2023 and bottomed at $31.0 million in Q1 2021.
  • The 5-year median for Other Operating Expenses is $40.4 million (2023), against an average of $41.2 million.
  • The largest annual shift saw Other Operating Expenses surged 88.81% in 2021 before it crashed 40.69% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $41.5 million in 2021, then dropped by 1.8% to $40.7 million in 2022, then surged by 65.41% to $67.4 million in 2023, then plummeted by 40.69% to $40.0 million in 2024, then grew by 7.94% to $43.1 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Other Operating Expenses are $43.1 million (Q4 2025), $42.1 million (Q3 2025), and $42.0 million (Q2 2025).